What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Palforzia demonstrated a clear clinical advantage by significantly improving tolerance to peanut protein compared to placebo in two Phase 3 trials (PALISADE and ARTEMIS). The results showed that 50.3% and 58.3% of participants could tolerate at least 1,000 mg of peanut protein, respectively, with statistically significant differences (p<0.0001). However, the evidence lacks direct clinical trial data on the reduction of severe allergic reactions, which prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for Palforzia fall within the acceptable range for Healthcare resources, with the base-case ICER reported at £23,745 per QALY gained. The committee acknowledged that additional benefits may not have been fully captured in the economic model, supporting a strong cost-effectiveness argument.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests that Palforzia likely improves quality of life for patients with peanut allergy, particularly once a stable dose is achieved. However, the exact impact on HRQoL is uncertain due to the reliance on utility values that were derived from various sources, including proxy reports, which may not accurately reflect the true quality of life improvements.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Palforzia has an acceptable safety profile, with most adverse events being mild to moderate. While there is an increased risk of treatment-related anaphylactic reactions, severe cases are rare. The overall safety data suggest that the treatment is manageable, although monitoring is required.
Was the drug compared against what payers expect? — Comparator Selection
The committee agreed that strict peanut avoidance is the most appropriate comparator for Palforzia, aligning with its marketing authorization. This direct comparison strengthens the evidence base for the treatment’s effectiveness.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a representative population of children aged 4 to 17 years with confirmed peanut allergy, which aligns well with the intended use of Palforzia. However, there are some concerns regarding the generalizability of results to the broader Healthcare population, particularly regarding the need for oral food challenges.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Palforzia can be integrated into existing care pathways with some adjustments, such as the need for monitoring and potential training for healthcare providers. The treatment requires structured dosing and clinic visits, which may necessitate some changes in practice but are manageable.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of implementing Palforzia are significant, particularly regarding the need for clinic visits and monitoring for anaphylaxis. The model did not fully account for the costs associated with setting up oral immunotherapy services, which raises concerns about the overall budget impact.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on two Phase 3 RCTs with a reasonable sample size and low risk of bias. However, the lack of direct evidence on the long-term effects and the reliance on surrogate endpoints slightly weaken the robustness of the evidence.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the long-term use of Palforzia and its impact on quality of life, the overall context of unmet need for peanut allergy treatments and the potential benefits of the therapy provide a favorable backdrop for its use.
